Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Donates License For Small-Molecule Compound Library To China, WHO

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Denmark-based Novo Nordisk will donate a license to its small molecule compound library to China's National Center for Drug Screening, the company announced April 28 in Copenhagen.

You may also be interested in...



Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China, Biopharma Center

$400 million facility is Novo’s largest offshore investment.

Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center

BEIJING - The Danish-headquartered biopharmaceutical outfit Novo Nordisk is building a massive, $400 million insulin plant in the Chinese east coast city of Tianjin to serve diabetes patients across China and Asia, according to company executives and government officials

Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China, Biopharma Center

$400 million facility is Novo’s largest offshore investment.

Related Content

UsernamePublicRestriction

Register

SC068466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel